呼吸指南

订阅

MedSci主页 / 所有栏目 / 呼吸指南

2021 ERS指南：阻塞性睡眠呼吸暂停的非CPAP治疗

2021-11-30 欧洲呼吸学会 Eur Respir Rev

阻塞性睡眠呼吸暂停睡眠呼吸障碍

2021年11月，欧洲呼吸学会(ERS)发布了阻塞性睡眠呼吸暂停的非CPAP治疗指南。成人阻塞性睡眠呼吸暂停治疗的新方法已在临床实践中被引入，本文主要针对非持续气道正压（CPAP）治疗提供指导建议，作

中文标题：

2021 ERS指南：阻塞性睡眠呼吸暂停的非CPAP治疗

英文标题：

European Respiratory Society guideline on non-CPAP therapies for obstructive sleep apnoea

发布机构：

欧洲呼吸学会

发布日期：

2021-11-30

简要介绍：

2021年11月，欧洲呼吸学会(ERS)发布了阻塞性睡眠呼吸暂停的非CPAP治疗指南。成人阻塞性睡眠呼吸暂停治疗的新方法已在临床实践中被引入，本文主要针对非持续气道正压（CPAP）治疗提供指导建议，作为2011年非CPAP治疗治疗声明的更新，已经成为临床指南。

相关资料下载：
[AttachmentFileName(sort=1, fileName=2021 ERS指南：阻塞性睡眠呼吸暂停的非CPAP治疗.pdf)] GetToolGuiderByIdResponse(projectId=1, id=cd6ad1c0022823eb, title=2021 ERS指南：阻塞性睡眠呼吸暂停的非CPAP治疗, enTitle=European Respiratory Society guideline on non-CPAP therapies for obstructive sleep apnoea, guiderFrom=Eur Respir Rev, authorId=0, author=, summary=2021年11月，欧洲呼吸学会(ERS)发布了阻塞性睡眠呼吸暂停的非CPAP治疗指南。成人阻塞性睡眠呼吸暂停治疗的新方法已在临床实践中被引入，本文主要针对非持续气道正压（CPAP）治疗提供指导建议，作, cover=https://img.medsci.cn/20211214/1639463852251_1614372.png, journalId=0, articlesId=null, associationId=172, associationName=欧洲呼吸学会, associationIntro=欧洲呼吸学会（ERS）是欧洲专业学会组织，是具有广泛基础的拥有100多个国家的大约一万名成员。内容涵盖了基础科学和临床医学。, copyright=0, guiderPublishedTime=Tue Nov 30 00:00:00 CST 2021, originalUrl=, linkOutUrl=, content=<p><span style="color: #373737;">2021年11月，欧洲呼吸学会(ERS)发布了阻塞性睡眠呼吸暂停的非CPAP治疗指南。成人阻塞性睡眠呼吸暂停治疗的新方法已在临床实践中被引入，本文主要针对非持续气道正压（CPAP）治疗提供指导建议，作为2011年非CPAP治疗治疗声明的更新，已经成为临床指南。</span></p>, tagList=[TagDto(tagId=3180, tagName=阻塞性睡眠呼吸暂停), TagDto(tagId=10035, tagName=睡眠呼吸障碍)], categoryList=[CategoryDto(categoryId=12, categoryName=呼吸, tenant=100), CategoryDto(categoryId=17, categoryName=神经科, tenant=100), CategoryDto(categoryId=30, categoryName=耳鼻咽喉, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=3180, guiderKeyword=阻塞性睡眠呼吸暂停, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=指南, guiderLanguage=1, guiderRegion=2, opened=0, paymentType=, paymentAmount=2, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=6081, appHits=251, showAppHits=0, pcHits=745, showPcHits=5829, likes=3, shares=21, comments=17, approvalStatus=1, publishedTime=Fri Dec 03 17:37:11 CST 2021, publishedTimeString=2021-11-30, pcVisible=1, appVisible=1, editorId=1614372, editor=MedSciZeng, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=3, createdBy=null, createdName=dajiong, createdTime=Fri Dec 03 16:53:39 CST 2021, updatedBy=1614372, updatedName=MedSciZeng, updatedTime=Sat Jan 06 16:47:22 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=2021 ERS指南：阻塞性睡眠呼吸暂停的非CPAP治疗.pdf)])
2021 ERS指南：阻塞性睡眠呼吸暂停的非CPAP治疗.pdf
下载请点击：
评论区 (13)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1211962, encodeId=9ac1121196247, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2a895651937, createdName=ms8000000618864745, createdTime=Sun Apr 17 18:37:01 CST 2022, time=2022-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1205820, encodeId=cb181205820cd, content=谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220325/3cf95d26ec4a4868a63bcc681e37dd4c/00862174d9b74167b2fc276a48282afb.jpg, createdBy=90866571354, createdName=ms9000001897942088, createdTime=Fri Mar 25 11:29:00 CST 2022, time=2022-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1193443, encodeId=fcfd119344351, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d9d36503575, createdName=ms8000001370935958, createdTime=Tue Feb 15 00:58:06 CST 2022, time=2022-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1190142, encodeId=871d1190142f0, content=感谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=3a655552216, createdName=ms2000001731088546, createdTime=Fri Feb 04 14:12:52 CST 2022, time=2022-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1083345, encodeId=50bc108334504, content=谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d25a5516768, createdName=一己怀, createdTime=Wed Dec 22 23:54:35 CST 2021, time=2021-12-22, status=1, ipAttribution=)]
    2022-04-17 ms8000000618864745

    学习

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1211962, encodeId=9ac1121196247, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2a895651937, createdName=ms8000000618864745, createdTime=Sun Apr 17 18:37:01 CST 2022, time=2022-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1205820, encodeId=cb181205820cd, content=谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220325/3cf95d26ec4a4868a63bcc681e37dd4c/00862174d9b74167b2fc276a48282afb.jpg, createdBy=90866571354, createdName=ms9000001897942088, createdTime=Fri Mar 25 11:29:00 CST 2022, time=2022-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1193443, encodeId=fcfd119344351, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d9d36503575, createdName=ms8000001370935958, createdTime=Tue Feb 15 00:58:06 CST 2022, time=2022-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1190142, encodeId=871d1190142f0, content=感谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=3a655552216, createdName=ms2000001731088546, createdTime=Fri Feb 04 14:12:52 CST 2022, time=2022-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1083345, encodeId=50bc108334504, content=谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d25a5516768, createdName=一己怀, createdTime=Wed Dec 22 23:54:35 CST 2021, time=2021-12-22, status=1, ipAttribution=)]
    2022-03-25 ms9000001897942088

    谢谢分享

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1211962, encodeId=9ac1121196247, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2a895651937, createdName=ms8000000618864745, createdTime=Sun Apr 17 18:37:01 CST 2022, time=2022-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1205820, encodeId=cb181205820cd, content=谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220325/3cf95d26ec4a4868a63bcc681e37dd4c/00862174d9b74167b2fc276a48282afb.jpg, createdBy=90866571354, createdName=ms9000001897942088, createdTime=Fri Mar 25 11:29:00 CST 2022, time=2022-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1193443, encodeId=fcfd119344351, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d9d36503575, createdName=ms8000001370935958, createdTime=Tue Feb 15 00:58:06 CST 2022, time=2022-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1190142, encodeId=871d1190142f0, content=感谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=3a655552216, createdName=ms2000001731088546, createdTime=Fri Feb 04 14:12:52 CST 2022, time=2022-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1083345, encodeId=50bc108334504, content=谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d25a5516768, createdName=一己怀, createdTime=Wed Dec 22 23:54:35 CST 2021, time=2021-12-22, status=1, ipAttribution=)]
    2022-02-15 ms8000001370935958

    学习

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1211962, encodeId=9ac1121196247, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2a895651937, createdName=ms8000000618864745, createdTime=Sun Apr 17 18:37:01 CST 2022, time=2022-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1205820, encodeId=cb181205820cd, content=谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220325/3cf95d26ec4a4868a63bcc681e37dd4c/00862174d9b74167b2fc276a48282afb.jpg, createdBy=90866571354, createdName=ms9000001897942088, createdTime=Fri Mar 25 11:29:00 CST 2022, time=2022-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1193443, encodeId=fcfd119344351, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d9d36503575, createdName=ms8000001370935958, createdTime=Tue Feb 15 00:58:06 CST 2022, time=2022-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1190142, encodeId=871d1190142f0, content=感谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=3a655552216, createdName=ms2000001731088546, createdTime=Fri Feb 04 14:12:52 CST 2022, time=2022-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1083345, encodeId=50bc108334504, content=谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d25a5516768, createdName=一己怀, createdTime=Wed Dec 22 23:54:35 CST 2021, time=2021-12-22, status=1, ipAttribution=)]
    2022-02-04 ms2000001731088546

    感谢分享

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1211962, encodeId=9ac1121196247, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2a895651937, createdName=ms8000000618864745, createdTime=Sun Apr 17 18:37:01 CST 2022, time=2022-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1205820, encodeId=cb181205820cd, content=谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220325/3cf95d26ec4a4868a63bcc681e37dd4c/00862174d9b74167b2fc276a48282afb.jpg, createdBy=90866571354, createdName=ms9000001897942088, createdTime=Fri Mar 25 11:29:00 CST 2022, time=2022-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1193443, encodeId=fcfd119344351, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d9d36503575, createdName=ms8000001370935958, createdTime=Tue Feb 15 00:58:06 CST 2022, time=2022-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1190142, encodeId=871d1190142f0, content=感谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=3a655552216, createdName=ms2000001731088546, createdTime=Fri Feb 04 14:12:52 CST 2022, time=2022-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1083345, encodeId=50bc108334504, content=谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d25a5516768, createdName=一己怀, createdTime=Wed Dec 22 23:54:35 CST 2021, time=2021-12-22, status=1, ipAttribution=)]
    2021-12-22 一己怀

    谢谢分享

    0

以上为热门评论，梅斯医学App还有更多内容

相关指南

美国睡眠医学会临床实践指南：将阻塞性睡眠呼吸暂停成人转诊至外科会诊

美国睡眠医学会(AASM,American Academy of Sleep Medicine) · 2021-08-05

将阻塞性睡眠呼吸暂停成人转诊至外科会诊：美国睡眠医学会系统评价、荟萃分析和 GRADE 评估

美国睡眠医学会(AASM,American Academy of Sleep Medicine) · 2021-08-15

2021 AHA科学声明：阻塞性睡眠呼吸暂停与心血管疾病

美国心脏协会(AHA,American Heart Association) · 2021-06-21

2021 NICE指南：16岁以上人群阻塞性睡眠呼吸暂停/低通气综合征和肥胖通气不良综合征（NG.202）

英国国家卫生与临床优化研究所(NICE,National Institute for Health and Clinical Excellence) · 2021-08-20

NCIE指南：16 岁以上阻塞性睡眠呼吸暂停/呼吸不足综合征和肥胖低通气综合征（NG202）

英国国家卫生与临床优化研究所(NICE,National Institute for Health and Clinical Excellence) · 2021-08-20

2021 AHA科学声明：儿童和青少年睡眠呼吸障碍与心血管疾病

美国心脏协会(AHA,American Heart Association) · 2021-08-18

拓展阅读

2010 阻塞性睡眠呼吸暂停与糖尿病专家共识

中华医学会呼吸病学分会 · 2010-05-01

阻塞性睡眠呼吸暂停低通气综合征诊治指南（2011修订版）

中华医学会呼吸病学分会 · 2012-01-01

阻塞性睡眠呼吸暂停低通气综合征患者持续气道正压通气临床应用专家共识(草案)

中华医学会呼吸病学分会 · 2012-01-01

2012 AAP儿童阻塞性睡眠呼吸暂停综合征的诊断与治疗指南

美国儿科学会(AAP,American Academy of Pediatrics) · 2012-08-27

2012 SAMBA共识：成人阻塞性睡眠呼吸暂停患者接受门诊手术的术前选择

门诊麻醉学会(SAMBA,The Society for Ambulatory Anesthesia) · 2012-11-01

2013 ERS/ESH 阻塞性睡眠呼吸暂停与高血压患者管理建议

欧洲呼吸学会(ERS,European Respiratory Society) · 2013-05-01